ArticleDiscover oncology2025
Neoadjuvant therapy demonstrates both safety and clinical feasibility for renal cell carcinoma patients with tumor thrombus.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combination of vascular surgery with novel vascular targeting agents as cancer therapeutics.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWhile the applications of neoadjuvant therapies on patients diagnosed with renal cell carcinoma (RCC) with tumor thrombus (TT) is growing, the safety of preoperative therapies has yet to be clarified.
methods451 patients diagnosed with RCC with TT undergoing radical nephrectomy and thrombectomy were included. Propensity score-matched cohorts were used to investigate the safety and feasibility of neoadjuvant therapies. We compared perioperative parameters and postoperative complications. Postoperative complications were assessed within 30 days of the operation and were graded using the Clavien-Dindo grading system. A Cox regression and Kaplan-Meier curves were used to assess the impact of neoadjuvant therapies on patients' overall survival (OS) and cancer-specific survival (CSS).
resultsAfter 1:3 ratio propensity-score matching (PSM), 56 patients receiving neoadjuvant therapy and 153 patients receiving non-neoadjuvant therapy were included in the analysis. No significant difference was found between the two groups after PSM in terms of baseline information (P > 0.05). The rate of blood transfusion (71.4% vs. 52.3%, P = 0.01) was higher in neoadjuvant therapy. 8 patients (14.3%) in neoadjuvant therapy group experienced serious complications while 15 patients (14.9%) in non-neoadjuvant therapy group experienced serious complications. The perioperative parameters and postoperative complications did not show significant differences in preoperative-combined therapy group and non-preoperative-combined therapy group. No significant differences were found in OS or CSS between the neoadjuvant therapy group and non-neoadjuvant therapy group.
conclusionsNeoadjuvant therapies can be safely administered to RCC patients with TT. Neoadjuvant therapies recipients' OS or CSS did not differ significantly from those who did not receive the treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.